- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Hubert Chen, MD
- Telefonnummer: 8587044660
- E-post: clinicaltrials@vikingtherapeutics.com
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85741
- Rekruttering
- Viking Clinical Site #2020
-
Ta kontakt med:
- Telefonnummer: 520-333-4515
-
-
California
-
Lake Forest, California, Forente stater, 92630
- Rekruttering
- Viking Clinical Site #2015
-
Ta kontakt med:
- Telefonnummer: 714-550-9990
-
-
Florida
-
Ocoee, Florida, Forente stater, 34761
- Rekruttering
- Viking Clinical Site #2059
-
Ta kontakt med:
- Telefonnummer: 407-654-2724
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Rekruttering
- Viking Clinical Site #2013
-
Ta kontakt med:
- Telefonnummer: 404-920-6201
-
-
Indiana
-
Evansville, Indiana, Forente stater, 47714
- Rekruttering
- Viking Clinical Site #2001
-
Ta kontakt med:
- Telefonnummer: 812-477-2760
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Viking Clinical Site #2046
-
Ta kontakt med:
- Telefonnummer: 504-336-2667
-
Valparaiso, Indiana, Forente stater, 46383
- Rekruttering
- Viking Clinical Site #2009
-
Ta kontakt med:
- Telefonnummer: 219-464-8302
-
-
Minnesota
-
Richfield, Minnesota, Forente stater, 55423
- Rekruttering
- Viking Clinical Site #2004
-
Ta kontakt med:
- Telefonnummer: 952-922-7000
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39206
- Rekruttering
- Viking Clinical Site #2029
-
Ta kontakt med:
- Telefonnummer: 770-330-4157
-
-
Missouri
-
Springfield, Missouri, Forente stater, 65807
- Rekruttering
- Viking Clinical Site #2028
-
Ta kontakt med:
- Telefonnummer: 504-338-0917
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87107
- Rekruttering
- Viking Clinical Site #2052
-
Ta kontakt med:
- Telefonnummer: 505-243-1627
-
-
New York
-
Binghamton, New York, Forente stater, 13905
- Rekruttering
- Viking Clinical Site #2039
-
Ta kontakt med:
- Telefonnummer: 607-800-5777
-
-
Oregon
-
Medford, Oregon, Forente stater, 97504
- Rekruttering
- Viking Clinical Site #2023
-
Ta kontakt med:
- Telefonnummer: 541-858-1018
-
-
Rhode Island
-
East Greenwich, Rhode Island, Forente stater, 02818
- Rekruttering
- Viking Clinical Site #2002
-
Ta kontakt med:
- Telefonnummer: 401-739-9350
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29407
- Rekruttering
- Viking Clinical Site #2044
-
Ta kontakt med:
- Telefonnummer: 843-432-2477
-
-
Tennessee
-
Hendersonville, Tennessee, Forente stater, 37075
- Rekruttering
- Viking Clinical Site #2030
-
Ta kontakt med:
- Telefonnummer: 504-339-0917
-
-
Texas
-
Abilene, Texas, Forente stater, 79606
- Rekruttering
- Viking Clinical Site #2031
-
Ta kontakt med:
- Telefonnummer: 325-400-1150
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Viking Clinical Site #2011
-
Ta kontakt med:
- Telefonnummer: 206-536-3030
-
Spokane, Washington, Forente stater, 99218
- Rekruttering
- Viking Clinical Site #2042
-
Ta kontakt med:
- Telefonnummer: 509-505-6227
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
Eksperimentell: Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Eksperimentell: Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Eksperimentell: Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Tidsramme: 68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- VK2735-305
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .